Previous studies suggest the excellent performance of the bioactive coated stent TITAN 2 compared with drug-eluting stents (DES). The aim of the study was to evaluate the results of this device in patients undergoing both ST segment elevation and without ST segment elevation acute coronary syndrome. A total of 1066 patients were included, of whom 83.8% were admitted experiencing a ST segment elevation heart attack.
The device allowed a high rate of direct stenting and good final TIMI flow. The rate of target lesion revascularization with the new device in this unselected population was lower than that reported in randomized studies. No differences between groups in terms of in-stent thrombosis were observed.
J.A. Gomez-Hospital
2014-05-23
Title: Final results of multicentre TITAN-AMI registry
